BEFORE THE UNITED STATES JUDICIAL PANEL ON MULTIDISTRICT LITIGATION

IN RE: FLUOROQUINOLONE § MDL DOCKET NO. 2642

PRODUCTS LIABILITY \$
LITIGATION \$

RESPONSE IN SUPPORT OF PLAINTIFFS' MOTION TO TRANSFER ACTIONS PURSUANT TO 28 U.S.C. § 1407 FOR COORDINATED OR CONSOLIDATED PROCEEDINGS

I. INTRODUCTION

Pursuant to 28 U.S.C. §1407 and Rule 6.2(e) of the United States Judicial Panel on Multidistrict Litigation Rules of Procedure, Plaintiffs Billie Stephens, Alan Lee Henness and Samantha Henness, and Earl Ricker and Patricia Ricker respectfully submit this Interested Party Response to the Motion to Transfer Actions for Coordinated or Consolidated Proceedings. As set forth herein, Plaintiffs agree that consolidation is appropriate and further submit that coordination before the Honorable David R. Herndon of the United States District Court, Southern District of Illinois is appropriate.

II. TRANSFER AND PRETRIAL COORDINATION IS APPROPRIATE UNDER of 28 U.S.C. § 1407

Plaintiffs adopt by reference and concur with the arguments presented by Heard Robins Cloud, LLP (Dkt. # 1-1; Filed 05/19/15), Aylstock, Witkin, Kreis & Overholtz, PLLC (Dkt. #22; Filed 06/05/15), and Gomez Trial Attorneys (Dkt. #37, Filed 07/13/2015) in their respective briefs.

Pursuant to 28 U.S.C. § 1407(a), the Panel favors transfer of civil actions to a single district for coordinated or consolidated pretrial proceedings when 1) the actions involve one or more common questions of fact, 2) transfer will be for the convenience of parties and witnesses, and 3) transfer promotes the just and efficient conduct of such actions. *See* 28 U.S.C. § 1407(a).

All three considerations support coordination or consolidation of all pending and subsequently filed Fluoroquinolone Products Liability actions.

Plaintiffs agree that transfer is useful and necessary given the multitude of actions filed and the numerous common questions of fact. All of the related Fluoroquinolone actions raise common questions of fact and law, including: whether the fluoroquinolones were defective; whether Defendants conducted adequate testing of the fluoroquinolones, whether Defendants breached their duties of care to Plaintiffs, whether Defendants had knowledge regarding the existence of the defects alleged, whether Defendants failed to warn physicians and consumers about the risks of the fluoroquinolones, whether Defendants breached any warranty related to its sale of fluoroquinolones, and whether the fluoroquinolones are capable of causing and/or did cause the irreversible peripheral neuropathy and related injuries. All of the Related Actions allege similar causes of action, namely, following a dose of Levaquin, Cipro and/or Avelox, the Plaintiff began to suffer debilitating and permanent symptoms of peripheral neuropathy.

Further, Plaintiffs agree that transfer for pretrial purposes would serve "the convenience of the parties and witnesses" and "promote the just and efficient conduct of the actions" as required by 28 USC 1407.

Currently, there are at least seventy-seven (77) substantially similar federal actions¹ filed by multiple different law firms in various federal district courts throughout the country against the named Defendants.² Due to the number of cases currently filed and the number of cases expected to be filed in the future, Plaintiffs support pretrial coordination or consolidation for

¹ See attached Schedule of Actions.

² At the time of this filing, Sill Law Group, PLLC represents five plaintiffs: Billie Stephens, in an action pending in the United States District Court for the Western District of Oklahoma; Alan Lee Henness and Samantha Henness, in an action pending in the Eastern District of Pennsylvania; and Earl Ricker and Patricia Ricker, in an action pending in the United States District Court for the District of Arizona.

convenience and as the most efficient and effective way of conducting the case. If the Panel decides not to centralize these actions, parties will risk duplicative discovery and inconsistent rulings that may harm Plaintiffs or Defendants. MDL Coordination or Consolidation at this stage, prior to substantive motions practice, will conserve judicial resources of all persons involved and will promote the just and efficient conduct actions.

Coordination or consolidation is also appropriate because this case involves multiple Defendants. There are at least eleven separate actions that allege exposure to different fluoroquinolones and therefore include both the Johnson & Johnson and Bayer entities as defendants. Defendants note this fact as a barrier to centralization; however, the Panel has often centralized litigations across an industry of drugs. *See e.g. In re: Androgel Prods. Liab. Litig.*, 24 F.Supp.3d 1378 (J.P.M.L. 2014). Levaquin, Cipro and Avelox are all among the same class of antibiotics: fluoroquinolones. Further, the warning label for all three antibiotics was updated at the same time to warn against the risk of Peripheral Neuropathy. The Food and Drug Administration required the update to all three antibiotics at the same time because it felt the risk was equal among the three drugs. Consequently, because there are multiple defendants, centralization for all fluoroquinolones is appropriate to expeditiously and efficiently litigate this case.

Defendant Johnson and Johnson's ("J&J") recent filings suggest it agrees with Plaintiffs on this issue. J&J recently filed an Administrative Motion in the Northern District of California requesting that the Levaquin actions be "related" under California Local Rules. Def's Mot. to Consider Whether Cases should be Related, *Lampard v. Johnson & Johnson et al.*, No. 3:14-cv-04983, ECF No. 56 (N.D. California July 7, 2015). Local Rule 3-12(a) allows "relation" when: "i) the actions involve substantially the same parties, and ii) it is likely there will be an unduly

burdensome duplication of labor or conflicting results if the cases are conducted before different judges." J&J argues these claims should be related because all cases involve "claims of peripheral neuropathy as a side effect of taking Levaquin, and because Defendants are represented by the same counsel in all three actions, relating *Lampard* and *Goldbaum* at this time is likely to conserve judicial resources of all counsel during the case management stage." *Id.* Similarly, Plaintiffs in the instant action argue in favor of consolidation because i) all of these cases involve common facts – fluoroquinolones causes peripheral neuropathy, ii) coordination or consolidation would be convenient for both parties, and iii) coordination or consolidation would limit duplicative discovery requests and efforts and "conserve judicial resources of all counsel during the case management stage." *Id.* As such, J&J cannot now oppose pretrial coordination or consolidation into one judicial district because Plaintiffs here make arguments identical to the arguments submitted by J&J in favor of "relating" the actions under California Local Rules.

III. ALL RELATED ACTIONS SHOULD BE TRANSFERRED FOR COORDINATION OR CONSOLIDATION TO THE SOUTHERN DISTRICT OF ILLINOIS IN FRONT OF JUDGE HERNDON

The United States District Court for the Southern District of Illinois is the most appropriate forum for coordination or consolidation of the fluoroquinolone litigation because it is conveniently located and has the capacity to expeditiously handle a case of this magnitude.

The Southern District of Illinois's courthouse in East St. Louis, Illinois is located approximately fifteen minutes from Lambert-St. Louis International Airport.³ Accordingly, travel to and from the courthouse is easily accessible to all parties and witnesses. Further, the

4

³ The Lambert-St. Louis International Airport is one of the most centrally located travel destinations in the country, offering affordable flights and more than 60 nonstop destinations.

Southern District of Illinois has experience handling complex litigations⁴ and is not currently overburdened with other complex matters. Presently, the Southern District of Illinois maintains only two multidistrict litigations and at least one of the litigations is now substantially resolved. *See In re Yasmin and Yaz (Dropirenone) Mtg., Sales Practices and Prods. Liab. Litig.*, 655 F. Supp. 2d 1343 (J.P.M.L. 2009).

Plaintiffs further submit that Judge David R. Herndon of the Southern District of Illinois, who has been assigned to at least two fluoroquinolone actions, one involving Levaquin and one involving Avelox, is an excellent choice for managing this litigation. Judge Herndon was appointed to the bench 17 years ago and has significant experience managing complex litigation and consolidated mass tort litigation in an efficient and effective manner. Judge Herndon is an experienced jurist who has proven his ability to manage a massive litigation with complex legal and medical issues.⁵ As such, Plaintiffs respectfully request the Panel transfer all pending and subsequently filed actions for coordination or consolidation in front of Judge David R. Herndon in the Southern District of Illinois.

IV. CONCLUSION

For the reasons set forth herein, and those presented in Herd Robins Cloud, LLP's brief in support of its motion for consolidation under 28 U.S.C. §1407, Aylstock, Witkin, Kreis & Overholtz, PLLC's Interested Party Response, and Gomez Trial Attorneys Interested Party

⁴ The Southern District of Illinois maintains a well-staffed and well-prepared Clerk's office ready to handle the influx of issues inherent in complex, multidistrict litigation. Further, the District maintains an updated webpage that provides accurate and up to date information and documents for attorneys and litigants. The District has also developed a streamlined process for direct filing of complaints.

⁵ See In re Yasmin and Yaz (Dropirenone), 655 F. Supp. 2d 1343 (Judge Herndon managed a docket with over 11,000 filed cases, ruled on over sixty (60) Motions in Limine and eighteen (18) Motions to Exclude the Testimony of Expert Witnesses pursuant to Daubert, entered sixty-seven (67) Case Management Orders22, and held over forty (40) status hearings).

Response, Plaintiffs respectfully request and join the motion to transfer all pending fluoroquinolone actions and all subsequently filed tag-along cases for coordinated or consolidated pretrial proceedings before the Southern District of Illinois, and assign the matter to Judge David. A. Herndon.

Dated: July 29, 2015 Respectfully Submitted,

By: /s/ Matthew J. Sill

Matthew J. Sill

SILL LAW GROUP, PLLC

14005 N. Eastern Ave. Edmond, OK 73013

Telephone: (405) 509-6300 Facsimile: (405) 509-6268 Email: matt@sill-law.com

Attorneys for Plaintiffs Billie Stephens, Alan Lee Henness and Samantha Henness, and Earl Ricker and Patricia Ricker

BEFORE THE UNITED STATES JUDICIAL PANEL ON MULTIDISTRICT LITIGATION

IN RE: FLUOROQUINOLONE **MDL - 2642**

§ § § PRODUCTS LIABILITY LITIGATION

SCHEDULE OF ACTIONS

| Case Caption | Court | Civil Action No. | Judge |
|---|---|---------------------|--------------------------|
| Plaintiff: | U.S.D.C. District of | 3:15-cv-08065 | Hon. David G. |
| Lori Lynn Street | Arizona (Prescott | | Campbell |
| | Division) | | |
| Defendants: | | | |
| Johnson & Johnson; Janssen Research | | | |
| & Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiffs: | U.S.D.C. District of | 2:15-cv-01186 | Hon. Steven P. Logan |
| Earl Ricker | Arizona (Phoenix | | |
| Patricia Ricker | Division) | | |
| Defendants: | | | |
| Bayer Healthcare Pharmaceuticals, | | | |
| Inc.; Bayer Corporation; McKesson | | | |
| Corporation | | | |
| Plaintiff: | U.S.D.C. Central District | 5:15-cv-01232 | Hon. Andre Birotte, Jr. |
| Kimberly A. Isaiah | of California (Eastern Division – Riverside) | | |
| Defendants: | , | | |
| Bayer Healthcare Pharmaceuticals, | | | |
| Inc.; Bayer Corporation; Johnson & | | | |
| Johnson; Janssen Pharmaceuticals, Inc.; | | | |
| Janssen Research & Development, | | | |
| LLC | | | |
| Plaintiff: | U.S.D.C. Central District | 8:15-cv-00868 | Hon. James V. Selna |
| Mateo Emiliano Lopez | of California (Southern | | |
| | Division – Santa Ana) | | |
| Defendants: | | | |
| Bayer Healthcare Pharmaceuticals Inc.; | | | |
| Merck & Co., Inc. | | | |
| Plaintiff: | U.S.D.C. Central District | 8:15-cv-00964 | Hon. Josephine L. Staton |
| Diane Standbridge Willey | of California (Southern | | |
| | Division – Santa Ana) | | |
| Defendants: | | | |

| Bayer Healthcare Pharmaceuticals, Inc.; | | | |
|---|---|---------------|-----------------------|
| Merck & Co., Inc. | | | |
| Plaintiff: | U.S.D.C. Central District | 2:15-cv-03120 | Hon. Fernando M. |
| Marla Lombard | of California (Western Division – Los Angeles) | 2.13 € | Olguin |
| Defendants: | | | |
| Bayer Healthcare Pharmaceuticals, | | | |
| Inc.; Bayer Corporation | | | |
| Plaintiff: | U.S.D.C. Central District | 2:15-cv-04210 | Hon. Fernando M. |
| Kyle Richardson | of California (Western Division – Los Angeles) | | Olguin |
| Defendants: | | | |
| Bayer Healthcare Pharmaceuticals, | | | |
| Inc.; Bayer Corporation | | | |
| Plaintiff: | U.S.D.C. Eastern District | 1:15-cv-00361 | Hon. Troy L. Nunley |
| Michael Francis Breene | of California (Fresno) | | |
| Defendants: | | | |
| Johnson & Johnson; Johnson & | | | |
| Johnson Pharmaceutical Research & | | | |
| Development, LLC; Ortho-McNeil- | | | |
| Janssen Pharmaceuticals, Inc.; | | | |
| McKesson Corporation | | | |
| Plaintiff: | U.S.D.C. Eastern District | 1:15-cv-00525 | Hon. Morrison C. |
| Felicita Cortez | of California (Fresno) | | England, Jr. |
| Defendants: | | | |
| Johnson & Johnson; Johnson & | | | |
| Johnson Pharmaceutical Research & | | | |
| Development, L.L.C.; Ortho- McNeil- | | | |
| Janssen Pharmaceuticals, Inc.; | | | |
| McKesson Corporation | | | |
| Plaintiff: | U.S.D.C. Eastern District | 1:15-cv-01166 | Hon. Anthony W. Ishii |
| Patricia Phoenix | of California (Fresno) | | j |
| Defendants: | | | |
| Bayer Healthcare Pharmaceuticals, Inc.; | | | |
| Bayer Corporation; Merck & Co., Inc.; | | | |
| Johnson & Johnson; Janssen Research & | | | |
| Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C. Eastern | 2:15-cv-01579 | Hon. Troy L. Nunley |
| Paige Hensley | District of California | | |
| | (Sacramento) | | |
| Defendants: | | | |

| Johnson & Johnson; Janssen | | | |
|---|--|---------------|------------------------|
| Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C. Eastern District | 2:15-cv-01612 | Hon. Morrison C. |
| Jeanette Dyer | of California (Sacramento) | 2.13-67-01012 | England, Jr. |
| Defendants: | | | |
| Johnson & Johnson; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C. Southern | 3:15-cv-00513 | Hon. Janis L. |
| Dennis Armenta | District of California (San Diego) | | Sammartino |
| Defendants: | | | |
| Johnson & Johnson; Johnson & | | | |
| Johnson Pharmaceutical Research & | | | |
| Development, L.L.C.; Ortho-McNeil- | | | |
| Janssen Pharmaceuticals, Inc.; | | | |
| McKesson Corporation | | | |
| Plaintiff: | U.S.D.C. Southern | 3:15-cv-01329 | Hon. Jeffrey T. Miller |
| Krista Ann Kirkwood | District of California (San Diego) | | |
| Defendants: | | | |
| Bayer Healthcare Pharmaceuticals, Inc.; | | | |
| Merck & Co., Inc. | | | |
| Plaintiff: | U.S.D.C. Northern | 3:14-cv-03680 | Hon. William Alsup |
| Sherri Kellerman | District of California | | |
| | (San Francisco) | | |
| Defendants: | , | | |
| Bayer Healthcare Pharmaceuticals, | | | |
| Inc.; Merck & Co., Inc.; Schering | | | |
| Corporation; McKesson Corporation | | | |
| Plaintiff: | U.S.D.C. Northern | 3:14-cv-04983 | Hon. Vince Chhabria |
| Simon Lampard | District of California (San Francisco) | | |
| Defendants: | | | |
| Johnson & Johnson; Janssen Research | | | |
| & Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C. Northern | 3:14-cv-05254 | Hon. Samuel Conti |
| Suzanne Higley | District of California | | |
| | (San Francisco) | | |
| Defendants: | , | | |
| Bayer Healthcare Pharmaceuticals, | | | |
| Inc.; Bayer Corporation; McKesson | | | |
| Corporation Corporation, Mercesson | | | |
| Plaintiff: | U.S.D.C. Northern | 3:15-cv-01555 | Hon. Vince Chhabria |

| Guillermo Goldbaum | District of California | | |
|---|--|---------------|------------------------|
| Guillermo Goldbaum | | | |
| Defendants: | (San Francisco) | | |
| Johnson & Johnson & | | | |
| Johnson Pharmaceutical Research & | | | |
| | | | |
| Development, LLC; Ortho-McNeil- | | | |
| Janssen Pharmaceuticals, Inc.; | | | |
| McKesson Corporation | HCDC N. d | 2.15 01.610 | II V' CILL' |
| Plaintiff: | U.S.D.C. Northern | 3:15-cv-01610 | Hon. Vince Chhabria |
| Scott Alan Reiman | District of California (San Francisco) | | |
| Defendants: | | | |
| Johnson & Johnson; Janssen Research | | | |
| & Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc.; McKesson | | | |
| Corporation | | | |
| Plaintiff: | U.S.D.C. District of | 1:15-cv-01169 | Hon. Raymond P. |
| Joanne Hanson | Colorado (Denver) | | Moore |
| | , , | | |
| Defendants: | | | |
| Bayer Healthcare Pharmaceuticals, Inc.; | | | |
| Bayer Corporation; Johnson & | | | |
| Johnson; Janssen Research & | | | |
| Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C. District of | 1:15-cv-01177 | Hon. Marcia S. Krieger |
| Walter Sanchez | Colorado (Denver) | | |
| | | | |
| Defendants: | | | |
| Johnson & Johnson; Janssen Research | | | |
| & Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C. District of | 1:15-cv-01562 | Hon. Nina Y. Wang |
| Kelli Chan | Colorado (Denver) | | 8 |
| | (| | |
| Defendants: | | | |
| Johnson & Johnson; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C. District of | 1:15-cv-01564 | Hon. William J. |
| Rose Gale-Goldberg | Colorado (Denver) | | Martinez |
| | (2011,01) | | |
| Defendants: | | | |
| Johnson & Johnson; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| | | | |
| Plaintiff: | U.S.D.C. District of | 1:15-cv-01567 | Hon. Kathleen M. |
| 1 141114111 | C.S.D.C. District of | 1.13 0, 01307 | Tion. Hadineen ivi. |

| Kim Monahan | Colorado (Denver) | | Tafoya |
|-------------------------------------|---------------------------|---------------|-------------------------|
| Defendants: | | | |
| Johnson & Johnson; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C. District of | 1:14-cv-01953 | Hon. Beryl A. Howell |
| Stephanie Heller | Columbia (Washington, DC) | | |
| Defendants: | | | |
| Bayer Healthcare Pharmaceuticals, | | | |
| Inc.; Merck & Co., Inc. | | | |
| Plaintiff: | U.S.D.C. District of | 3:15-cv-01046 | Hon. Jeffrey A. Meyer |
| Kelly Najera Morales | Connecticut (New Haven) | | |
| Defendants: | | | |
| Johnson & Johnson; Janssen Research | | | |
| & Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C Middle District | 2:15-cv-00376 | Hon. John E. Steele |
| Ivan Webb | of Florida (Ft. Meyers) | | |
| Defendants: | | | |
| Johnson & Johnson; Janssen | | | |
| Pharmaceuticals, Inc. | | 2 1 5 00 11 1 | 77 71 7 6 |
| Plaintiff: | U.S.D.C Middle District | 2:15-cv-00411 | Hon. John E. Steele |
| Darryl Green | of Florida (Ft. Meyers) | | |
| Defendants: | | | |
| Johnson & Johnson; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C Middle District | 5:15-cv-00330 | Hon. James S. Moody, |
| Virginia Kaplan | of Florida (Ocala) | | Jr. |
| Defendants: | | | |
| Johnson & Johnson; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C Middle District | 6:15-cv-00892 | Hon. Roy B. Dalton, Jr. |
| Timothy Scribano | of Florida (Orlando) | | |
| Defendants: | | | |
| Johnson & Johnson; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C Middle District | 8:15-cv-01269 | Hon. Steven D. |
| Sharon Mandel | of Florida (Tampa) | | Merryday |
| Defendants: | | | |

| Bayer Healthcare Pharmaceuticals, | | | |
|--|-------------------------|---------------|-------------------------|
| Inc.; Merck & Co., Inc. | | | |
| Plaintiff: | U.S.D.C Middle District | 8:15-cv-01352 | Hon. Susan C. Bucklew |
| Sylvia Stephens McRae | of Florida (Tampa) | | |
| | 1 / | | |
| Defendants: | | | |
| Johnson & Johnson; Janssen Research | | | |
| & Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C Middle District | 8:15-cv-01391 | Hon. Richard A. Lazzara |
| Deborah Searcy | of Florida (Tampa) | | |
| | | | |
| Defendants: | | | |
| Bayer Corporation; Bayer Healthcare | | | |
| Pharmaceuticals, Inc.; Merck & Co., | | | |
| Inc. | | | |
| Plaintiff: | U.S.D.C. Southern | 0:15-cv-61189 | Hon. Darrin P. Gayles |
| Ronen Wolf | District of Florida | | |
| | (Ft. Lauderdale) | | |
| Defendants: | | | |
| Johnson & Johnson; Janssen Research | | | |
| & Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C. Northern | 1:15-cv-01293 | Hon. Richard W. Story |
| Kathy D. Presley | District of Georgia | | |
| | (Atlanta) | | |
| Defendants: | | | |
| Johnson & Johnson; Janssen Research | | | |
| & Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C. Northern | 1:15-cv-2652 | Pending Assignment |
| Marita Flanagan | District of Georgia | | |
| D.C. I. | (Atlanta) | | |
| Defendants: | | | |
| Bayer Corporation; Bayer HealthCare | | | |
| Pharmaceuticals, Inc.; Merck & Co., Inc. | HODONA | 1 15 2652 | D 1' A ' |
| Plaintiff: | U.S.D.C. Northern | 1:15-cv-2653 | Pending Assignment |
| Brenda Rodgers | District of Georgia | | |
| Defendents | (Atlanta) | | |
| Defendants: | | | |
| Johnson & Johnson; Janssen Research & | | | |
| Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc. | IICDC Northorn | 2.15 av 00122 | Hon Dishard W. Cta |
| Plaintiff: | U.S.D.C. Northern | 2:15-cv-00133 | Hon. Richard W. Story |
| Pamela J. Lewis | District of Georgia | | |
| Defendants: | (Gainesville) | | |

| I-1 0 I-1 I D1 | | | T |
|---|---|---------------|-----------------------------|
| Johnson & Johnson; Janssen Research | | | |
| & Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc. | HCDCN | 2.15 00150 | II MAIN C |
| Plaintiffs: | U.S.D.C. Northern | 2:15-cv-00159 | Hon. William C. |
| Christopher P. Krebs | District of Georgia | | O'Kelley |
| Donna Krebs | (Gainesville) | | |
| Defendants: | | | |
| Johnson & Johnson; Janssen Research | | | |
| & Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc.; McKesson | | | |
| Corporation | | | |
| Plaintiff: | U.S.D.C. Northern | 3:15-cv-00120 | Hon. Timothy C. Batten, |
| Joseph Schwoebel | District of Georgia | | Sr. |
| | (Newnan) | | |
| Defendants: | | | |
| Bayer Healthcare Pharmaceuticals, Inc.; | | | |
| Bayer Corporation; Merck & Co., Inc.; | | | |
| Johnson & Johnson; Janssen Research & | | | |
| Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C. Northern | 1:15-cv-04933 | Hon. Milton I. Shadur |
| Patricia Jone Hobbs | District of Illinois | | |
| | (Chicago) | | |
| Defendants: | (====================================== | | |
| Bayer Healthcare Pharmaceuticals, Inc.; | | | |
| Bayer Corporation; Merck & Co., Inc.; | | | |
| Johnson & Johnson; Janssen Research | | | |
| & Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C. Northern | 1:15-cv-06530 | Hon. Edmond E. Chang |
| Michael Kaferly | District of Illinois | 1.15 CV 00550 | Tion. Lamona E. Chang |
| Whender Karerry | (Chicago) | | |
| Defendants: | (Cincago) | | |
| Bayer HealthCare Pharmaceuticals, | | | |
| Inc.; Bayer Corporation; Merck & Co., | | | |
| Inc.; Johnson & Johnson; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiffs: | U.S.D.C. Northern | 1:15-cv-06533 | Hon. Manish S. Shah |
| Diane Gustafson | District of Illinois | 1.13-64-00333 | 11011. Iviailisii 3. Siiaii |
| Gus Gustafson | | | |
| Ous Oustaison | (Chicago) | | |
| Defendants: | | | |
| Johnson & Johnson; Janssen Research | | | |
| & Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc.; Bayer | | | |

| | | | T |
|---------------------------------------|---------------------------------------|---------------|-----------------------|
| Corporation; Bayer Healthcare | | | |
| Pharmaceuticals, Inc.; Merck & Co., | | | |
| Inc.; Schering Corporation; McKesson | | | |
| Corporation | | | |
| Plaintiff: | U.S.D.C. Southern | 3:15-cv-00038 | Hon. David R. Herndon |
| Jeanne Bullard | District of Illinois (East St. Louis) | | |
| Defendants: | | | |
| Bayer Healthcare Pharmaceuticals, | | | |
| Inc.; Merck & Co., Inc. | | | |
| Plaintiff: | U.S.D.C. Southern | 3:15-cv-00452 | Hon. David R. Herndon |
| Nancy Lee Bush | District of Illinois (East St. Louis) | | |
| Defendants: | | | |
| Janssen Research & Development, | | | |
| LLC; Johnson & Johnson; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C. Northern | 3:15-cv-03131 | Hon. Mark W. Bennett |
| Steven Lundberg | District of Iowa (Central Division) | | |
| Defendants: | | | |
| Johnson & Johnson; Johnson & | | | |
| Johnson Pharmaceutical Research & | | | |
| Development, LLC; Ortho-McNeil- | | | |
| Janssen Pharmaceuticals, Inc.; | | | |
| McKesson Corporation | | | |
| Plaintiff: | U.S.D.C. District of | 6:15-cv-01226 | Hon. Eric F. Melgren |
| Mark Chrisman Perkins | Kansas (Wichita) | 0.13-67-01220 | Holl. Life 1. Weighti |
| Defendants: | | | |
| Johnson & Johnson; Janssen Research | | | |
| & Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C. Western | 3:15-cv-00293 | Hon. David J. Hale |
| Jeffrey Baum | District of Kentucky (Louisville) | | |
| Defendants: | , | | |
| Johnson & Johnson; Janssen Research | | | |
| & Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C. Eastern District | 2:15-cv-02570 | Hon, Lance M. Africk |
| Danny Keith Phillips | of Louisiana (New Orleans) | | |
| Defendants: | · · · · · · · | | |
| Bayer Healthcare Pharmaceuticals, | | | |
| Inc.; Bayer Corporation; Merck & Co., | | | |
| ,, | 1 | I | 1 |

| Ing. Johnson & Johnson, Joneson | | 1 | T |
|-------------------------------------|---|---------------|-------------------------|
| Inc.; Johnson & Johnson; Janssen | | | |
| Research & Development, LLC; | | | |
| Janssen Pharmaceuticals, Inc. | | 115 0100 | |
| Plaintiff: | U.S.D.C. District of | 1:15-cv-01082 | Hon. James K. Bredar |
| Karyn Joy Grossman | Maryland (Baltimore) | | |
| Defendants: | | | |
| Johnson & Johnson; Johnson & | | | |
| Johnson Pharmaceutical Research & | | | |
| Development, L.L.C.; Ortho-McNeil- | | | |
| Janssen Pharmaceuticals, Inc. | | | |
| Plaintiffs: | U.S.D.C. District of | 1:15-cv-13014 | Hon. Richard G. Stearns |
| Giovanna Rindini | Massachusetts (Boston) | | |
| Michael Rindini | | | |
| Defendants: | | | |
| Johnson & Johnson; Janssen Research | | | |
| * | | | |
| & Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc.; McKesson | | | |
| Corporation | Hab a birir a | 0.14 0.5021 | W. D. W. D. 1 |
| Plaintiff: | U.S.D.C. District of | 0:14-cv-05021 | Hon. Donovan W. Frank |
| Kathleen M. Smith | Minnesota | | |
| Defendants: | | | |
| Johnson & Johnson; Janssen Research | | | |
| & Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C. Southern | 2:15-cv-00084 | Hon. Keith Starrett |
| Gary Clark | District of Mississippi | | |
| , | (Eastern (Hattiesburg)) | | |
| Defendants: | | | |
| Johnson & Johnson; Janssen Research | | | |
| & Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C. Northern | 1:15-cv-00103 | Hon. Sharion Aycock |
| Rickey C. Talley | District of Mississippi | 1.15 67 00103 | 11011. Shurion Hycock |
| There y C. Tuney | (Aberdeen Division) | | |
| Defendants: | (= ==================================== | | |
| Johnson & Johnson; Janssen Research | | | |
| & Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Diointiff. | HCDC Western | 4.15 ov 00510 | Hon. Robert E. Larsen |
| Plaintiff: | U.S.D.C. Western | 4:15-cv-00519 | non. Kobert E. Larsen |
| Alana Smith | District of Missouri (Kansas City) | | |
| Defendants: | (Ixunous City) | | |
| | 1 | ı | I. |

| Johnson & Johnson; Janssen Research | | | |
|-------------------------------------|--------------------------|---------------|---------------------------------------|
| & Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C. District of | 4:15-cv-03020 | Hon. John M. Gerrard |
| Geraldine Blackmon | | 4:13-CV-03020 | Hon. John W. Gerrard |
| Geraldine Blackinon | Nebraska (4 Lincoln) | | |
| Defendants: | | | |
| Bayer Healthcare Pharmaceuticals, | | | |
| Inc.; Merck & Co., Inc. | | | |
| Plaintiff: | U.S.D.C. District of New | 1:15-cv-00468 | Hon. Stephan M. |
| John R. Taylor | Mexico (Albuquerque) | | Vidmar |
| j | | | |
| Defendants: | | | |
| Bayer Corporation; Bayer Healthcare | | | |
| Pharmaceuticals, Inc.; Merck & Co., | | | |
| Inc. | | | |
| Plaintiff: | U.S.D.C. Southern | 1:15-cv-03021 | Hon. Jed S. Rakoff |
| Olga Spiegel | District of New York | | |
| 818. | (Foley Square) | | |
| Defendants: | | | |
| Johnson & Johnson; Janssen Research | | | |
| & Development, L.L.C.; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C. Western | 3:15-cv-00194 | Hon. Max O. Cogburn, |
| Amy King | District of North | | Jr. |
| , , | Carolina (Charlotte) | | |
| Defendants: | , | | |
| Bayer Corporation; Bayer Healthcare | | | |
| Pharmaceuticals, Inc.; Merck & Co., | | | |
| Inc. | | | |
| Plaintiff: | U.S.D.C. Northern | 4:15-cv-00362 | Hon. Gregory K. |
| Billie Stephens | District of Oklahoma | | Frizzell |
| 2v 2p | (Tulsa) | | |
| Defendants: | | | |
| Johnson & Johnson; Janssen Research | | | |
| & Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc.; McKesson | | | |
| Corporation Corporation | | | |
| Plaintiff: | U.S.D.C. Western | 5:15-cv-00647 | Hon. Vicki Miles- |
| Sarah Rachel Moll | District of Oklahoma | 3.12 0, 30017 | LaGrange |
| | (Oklahoma City) | | |
| Defendants: | | | |
| Johnson & Johnson; Janssen Research | | | |
| & Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C. Western | 5:15-cv-00698 | Hon. Timothy D. |
| | 0.D.D.O. 11 OBIOTH | 2.12 21 00070 | i i i i i i i i i i i i i i i i i i i |

| L-1'- A C | District of Oldelahama | | D-Citi |
|---|---------------------------|---------------|---|
| Julie Ann Spaan | District of Oklahoma | | DeGiusti |
| D-6 14 | (Oklahoma City) | | |
| Defendants: | | | |
| Johnson & Johnson; Janssen Research | | | |
| & Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiffs: | U.S.D.C. District of | 6:15-cv-01394 | Hon. Thomas M. Coffin |
| Alan Wasner | Oregon (Eugene (6)) | | |
| Cynthia Wasner | | | |
| Defendants: | | | |
| Bayer HealthCare Pharmaceuticals, Inc.; | | | |
| Bayer Corporation; Merck & Co., Inc; | | | |
| Johnson & Johnson; Janssen Research & | | | |
| Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiffs: | U.S.D.C. Eastern District | 2:15-cv-03636 | Hon. Gerald A. McHugh |
| Alan Lee Henness | of Pennsylvania | 2.10 0. 00000 | |
| Samantha Henness | (Philadelphia) | | |
| Summing Homess | (Timacipina) | | |
| Defendants: | | | |
| Johnson & Johnson; Janssen Research | | | |
| & Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc.; McKesson | | | |
| Corporation | | | |
| Plaintiff: | U.S.D.C. Eastern District | 2:15-cv-03733 | Hon. Eduardo C. |
| Lori Murphy | of Pennsylvania | | Robreno |
| 1 0 | (Philadelphia) | | |
| Defendants: | 1 / | | |
| Johnson & Johnson; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C. Eastern District | 2:15-cy-03734 | Hon. Timothy J. Savage |
| Diego Vasquez | of Pennsylvania | | J v v v v v v v v v v v v v v v v v v v |
| | (Philadelphia) | | |
| Defendants: | ,, | | |
| Johnson & Johnson; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C. Eastern District | 2:15-cv-04135 | Hon. J. Curtis Joiner |
| Michelle Amrit Kaur | of Pennsylvania | 2.13 0, 01133 | 11011. U. Cuitio Joinei |
| Transit I I I I I I I I I I I I I I I I I I I | OI I OIIIIO YI VAIIIA | | |
| Defendants: | | | |
| Johnson & Johnson; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiffs: | U.S.D.C. Middle District | 1:15-cv-00479 | Hon. Sylvia H. Rambo |
| Robert L. Heffelfinger | of Pennsylvania | | |
| Celia Heffelfinger | (Harrisburg) | | |
| | (// | 1 | 1 |

| | I | 1 | |
|---|---------------------------|---------------|-------------------------|
| Defendants: | | | |
| Bayer Healthcare Pharmaceuticals, | | | |
| Inc.; Merck & Co., Inc. | | | |
| Plaintiff: | U.S.D.C. Middle District | 3:15-cv-01260 | Hon. Malachy E. |
| Gordon C. Olsommer | of Pennsylvania | 3.13 67 01200 | Mannion |
| | (Scranton) | | |
| Defendants: | (2 | | |
| Johnson & Johnson; Janssen Research | | | |
| & Development, LLC; | | | |
| Janssen Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C. District of | 4:15-cv-01322 | Hon. R. Bryan Harwell |
| Christina Morris | South Carolina | | |
| | (Florence) | | |
| Defendants: | | | |
| Bayer Healthcare Pharmaceuticals, | | | |
| Inc.; Merck & Co., Inc. | | | |
| Plaintiff: | U.S.D.C. District of | 5:15-cv-00118 | Hon. Geoffrey W. |
| Bonnie Lynch | Vermont (Rutland) | | Crawford |
| | | | |
| Defendants: | | | |
| Johnson & Johnson; Janssen Research | | | |
| & Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc. Plaintiff: | Habar Pivit | 1.15 00040 | D 1: A : |
| John D. Antone | U.S.D.C. Eastern District | 1:15-cv-00949 | Pending Assignment |
| John D. Antone | of Virginia | | |
| Defendants: | | | |
| Johnson & Jonson; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C. Western | 3:15-cv-05283 | Hon. Benjamin H. Settle |
| Ronald Baughn | District of Washington | | |
| | (Tacoma) | | |
| Defendants: | | | |
| Johnson & Johnson; Janssen Research | | | |
| & Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc.; McKesson | | | |
| Corporation | | | |
| Plaintiff: | U.S.D.C. Western | 3:15-cv-05511 | Hon. Ronald B. |
| Neal Lightle | District of Washington | | Leighton |
| | (Tacoma) | | |
| Defendants: | | | |
| McKesson Corporation; Johnson & | | | |
| Johnson; Janssen Pharmaceuticals, Inc.; | | | |
| Janssen Research & Development, | | | |
| LLC | | | |

| Plaintiff: | U.S.D.C. Southern | 5:15-cv-11546 | Pending Assignment |
|---|---------------------------|---------------|--------------------|
| Ardieth Paynter | District of West Virginia | | |
| | (Beckley) | | |
| Defendants: | - | | |
| Bayer Healthcare Pharmaceuticals, Inc.; | | | |
| Bayer Corporation; Merck & Co., Inc.; | | | |
| Johnson & Johnson; Janssen Research & | | | |
| Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C Southern | 2:15-cv-07638 | Hon. John T. |
| Rebecca Hatfield | District of West Virginia | | Copenhaver, Jr. |
| | (Charleston) | | |
| Defendants: | | | |
| Bayer Healthcare Pharmaceuticals, Inc.; | | | |
| Bayer Corporation; Merck & Co., Inc.; | | | |
| Johnson & Johnson; Janssen Research | | | |
| & Development, LLC; Janssen | | | |
| Pharmaceuticals, Inc. | | | |
| Plaintiff: | U.S.D.C. Eastern District | 1:15-cv-00691 | Hon. William C. |
| Robert Meyer | of Wisconsin (Green | | Griesbach |
| | Bay) | | |
| Defendants: | | | |
| Johnson & Johnson Services, Inc.; | | | |
| Janssen Research & Development, | | | |
| LLC; Janssen Pharmaceuticals, Inc. | | | |

BEFORE THE UNITED STATES JUDICIAL PANEL ON MULTIDISTRICT LITIGATION

IN RE: FLUOROQUINOLONE § MDL DOCKET NO. 2642

PRODUCTS LIABILITY §
LITIGATION §

PROOF OF SERVICE

I, Matthew J. Sill, hereby certify that on this 29th day of July, 2015, I electronically filed Response In Support of Plaintiffs' Motion To Transfer Actions Pursuant to 28 U.S.C. § 1407 for Coordinated or Consolidated Proceedings with the Court using the CM/ECF system and thereby delivered by electronic means to all registered participants as identified on the Notice of Electronic Filing:

Dated: July 29, 2015 Respectfully Submitted,

By: /s/ Matthew J. Sill

Matthew J. Sill

SILL LAW GROUP, PLLC

14005 N. Eastern Ave. Edmond, OK 73013 Telephone: (405) 509-6300

Facsimile: (405) 509-6268 Email: matt@sill-law.com

Attorneys for Plaintiffs Billie Stephens,

Alan Lee Henness and Samantha Henness, and

Earl Ricker and Patricia Ricker